Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study

Abstract

Efficacy of vibegron, a novel b3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study ConclusionsVibegron, a novel b3-adrenoreceptor agonist, significantly reduced the number of UUI episodes/day and significantly increased the voided volume/micturition in patients with OAB including those with severe UUI, with the response rate exceeding 50%. These results suggest that vibegron can be an effective therapeutic option for OAB patients with UUI.Keywords urgency urinary incontinence, overactive bladder, b3adrenoreceptor agonist, vibegron, post hoc analysis

Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment

“…The most common drug-related TEAEs of vibegron were dry mouth and constipation; however, the incidence of dry mouth was similar to placebo. A post hoc analysis of the same RCT, 46 vibegron significantly reduced the number of UUI episodes/day and significantly increased the voided volume/micturition in patients with OAB, with a response rate exceeding 50%. Changes in numbers of UUI episodes at week 12 in the V50, V100 and placebo groups, respectively, were −1.35, −1.47 and −1.08 in all patients and −2.95, −3.28 and −2.10 in the severe UUI subgroup.…”

Psychiatric History and Overactive Bladder Symptom Severity in Ambulatory Urogynecological Patients

“…The course and severity of OAB, including the presence or absence of UUI, are of primary importance for planning OAB treatment [4,23,24]. Given the above, surprisingly little is known about any possible relationship between a lifetime psychiatric history and psychotropic medications currently taken and the severity of OAB, including UUI, in ambulatory urogynecological patients.…”

Guidelines on urinary incontinence: it is time to join forces!

“…Although the management of urinary incontinence is well defined and excellently summarised by Sussman et al [1], treatment often remains demanding in daily clinical practice due to insufficient effectiveness or relevant side effects, so that new therapeutic options are urgently needed. Vibegron is a novel β3‐adrenoreceptor agonist, and Yoshida et al [2] present in the current issue of the BJUI promising findings with this drug for treating severe urgency urinary incontinence related to overactive bladder. In a post hoc analysis of a randomised, placebo‐controlled, double‐blind, comparative phase 3 study [3], vibegron significantly reduced the number of urgency urinary incontinence episodes and significantly increased voided volume per micturition with a response rate exceeding 50% [2].…”

“…Vibegron is a novel β3‐adrenoreceptor agonist, and Yoshida et al [2] present in the current issue of the BJUI promising findings with this drug for treating severe urgency urinary incontinence related to overactive bladder. In a post hoc analysis of a randomised, placebo‐controlled, double‐blind, comparative phase 3 study [3], vibegron significantly reduced the number of urgency urinary incontinence episodes and significantly increased voided volume per micturition with a response rate exceeding 50% [2]. These results are encouraging and warrant further randomised controlled trials, but also vibegron seems not to be a miracle agent showing effects in the range of mirabegron or antimuscarinics.…”